STOCK TITAN
  1. Home
  2. Sec-filings
  3. ASND
  4. [Form 3] Ascendis Pharma A/S Initial Statement of Beneficial Ownership

Ascendis Pharma (ASND) EVP details initial Form 3 equity holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Ascendis Pharma A/S executive Jay Donovan Wu filed an initial Form 3 reporting his equity holdings. He holds warrants covering 45,078 ordinary shares at an exercise price of 131.57 per share expiring on January 14, 2035, restricted stock units for 3,333 and 9,553 ordinary shares that vest in equal annual installments beginning on March 1, 2027, and 1,068 ordinary shares (including ADS) directly.

Positive

  • None.

Negative

  • None.
Insider Wu Jay Donovan
Role EVP & President US Market
Type Security Shares Price Value
holding Warrants -- -- --
holding Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Warrants — 45,078 shares (Direct); Restricted Stock Units — 3,333 shares (Direct); Ordinary Shares — 1,068 shares (Direct)
Footnotes (1)
  1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share. The warrants vested 25% on January 14, 2026 and thereafter in 36 equal monthly installments. The restricted stock units vest in two equal annual installments beginning on March 1, 2027. Each restricted stock unit represents a contingent right to receive one ADS. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Wu Jay Donovan
(Last)(First)(Middle)
C/O ASCENDIS PHARMA A/S
TUBORG BOULEVARD 12
(Street)
HELLERUPDK-2900
(City)(State)(Zip)
DENMARK
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & President US Market
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)1,068D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrants (2)01/14/2035Ordinary Shares45,078$131.57D
Restricted Stock Units (3) (3)Ordinary Shares3,333(4)D
Restricted Stock Units (5) (5)Ordinary Shares9,553(4)D
Explanation of Responses:
1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
2. The warrants vested 25% on January 14, 2026 and thereafter in 36 equal monthly installments.
3. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
4. Each restricted stock unit represents a contingent right to receive one ADS.
5. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
/s/ Michael Wolff Jensen as attorney-in-fact for Jay Wu03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Ascendis Pharma (ASND) Form 3 filing by Jay Donovan Wu show?

The Form 3 shows that executive Jay Donovan Wu reported initial holdings in Ascendis Pharma A/S, including warrants, restricted stock units, and ordinary shares. It establishes his baseline ownership position as EVP & President US Market at the company.

How many shares are covered by Jay Donovan Wu’s warrants in Ascendis Pharma (ASND)?

Jay Donovan Wu holds warrants covering 45,078 ordinary shares of Ascendis Pharma A/S. These warrants have an exercise price of 131.57 per share and expire on January 14, 2035, with vesting beginning on January 14, 2026 and continuing monthly.

What restricted stock unit awards does Jay Donovan Wu report in Ascendis Pharma (ASND)?

He reports two restricted stock unit awards: 3,333 units and 9,553 units, each representing a right to receive one ADS or ordinary share. These RSUs vest in two and three equal annual installments respectively, starting on March 1, 2027.

How many Ascendis Pharma (ASND) ordinary shares does Jay Donovan Wu directly hold?

The filing shows that Jay Donovan Wu directly holds 1,068 ordinary shares, including American Depositary Shares. Each ADS represents one ordinary share, so this figure reflects his direct share-equivalent ownership position separate from derivative and RSU holdings.

What does the Form 3 say about American Depositary Shares (ADS) for Ascendis Pharma (ASND)?

The filing explains that each American Depositary Share (ADS) represents one ordinary share of Ascendis Pharma A/S. It also notes that each restricted stock unit corresponds to a contingent right to receive one ADS, aligning RSU awards with ordinary share equivalents.